David A. Siegel Actinium Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$7.15 - $9.39 $350,092 - $459,771	-48,964 Reduced 36.56%	84,952 $630,000
Q1 2023 May 15, 2023	SELL	$8.51 - $14.26 $896,954 - $1.5 Million	-105,400 Reduced 44.04%	133,916 $1.27 Million
Q4 2022 Feb 14, 2023	BUY	$9.71 - $12.51 $1.89 Million - $2.44 Million	195,100 Added 441.24%	239,316 $2.55 Million
Q3 2022 Nov 14, 2022	BUY	$4.81 - $8.48 $90,427 - $159,424	18,800 Added 73.97%	44,216 $326,000
Q2 2022 Aug 15, 2022	BUY	$4.71 - $7.11 $119,709 - $180,707	25,416 New	25,416 $122,000

Q1 2021 May 17, 2021	SELL	$7.62 - $9.79 $76,200 - $97,899	-10,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$7.8 - $12.64 $78,000 - $126,400	10,000 New	10,000 $78,000

6.65M

369K

148K

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $186M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.